Drug delivery platform for the local biological therapy of ocular inflammation

Description of the granted funding

Inflammation of the eye (also called uveitis) affects young adults aged 20-50 (sometimes also children) and can lead to blindness. Biological therapeutics are very effective in the treatment of ocular inflammation, however they must be administered systemically and can cause serious side-effects, including cancer. This project aims to develop a novel treatment that allows the safe and effective delivery of biological therapeutics directly to the eye. This local delivery is achieved by using short pieces of RNA called aptamers that can target the biological therapeutics to the inflammation site inside the eye.The method used to find these aptamers is called SELEX. Aptamer-targeted biological therapeutics are also embedded inside hydrogels, this allows their prolonged release and thus decreases the administration frequency. Overall, this project will develop a safer and more comfortable treatment for patients with ocular inflammation and thus decrease their risk of getting blind.
Show more

Starting year

2020

End year

2026

Granted funding

Astrid Subrizi Orcid -palvelun logo
438 874 €

Related funding decisions

336280
Research costs of Academy Research Fellows(2020)
231 806 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

333301

Fields of science

Pharmacy

Research fields

Farmasia

Identified topics

eyes, eye diseases